What is Unlearn.AI?
Founded in 2017 by former Pfizer principal scientist Charles Fisher, Unlearn.AI is at the forefront of creating 'digital twins' to populate intelligent control arms in clinical studies. These digital twins are longitudinal, computationally generated clinical records that predict what would have happened if a specific patient received a placebo. By integrating data from real patients, Unlearn.AI's technology aims to replace traditional placebo-controlled cohorts, potentially reducing the number of participants needed for trials. This innovation could also enhance study power by decreasing variability and enabling deeper insights into patient responses to experimental treatments. The company is currently focusing its DiGenesis machine learning platform on complex diseases such as Alzheimer's and multiple sclerosis, areas with significant unmet medical needs.
How much funding has Unlearn.AI raised?
Unlearn.AI has raised a total of $180M across 5 funding rounds:
Series A
$15M
Other Financing Round
$15M
Multiple Rounds
$150M
Series A (2020): $15M with participation from DCVC Bio, 8VC, DCVC, Mubadala Capital Ventures, and Eisai
Other Financing Round (2023): $15M led by Wittington Ventures and Radical Ventures
Series C (2024): $50M supported by Altimeter Capital, Radical Ventures, Wittington Ventures, and Mubadala
Series C (2024): $50M featuring Wittington Ventures, Radical Ventures, Mubadala, and Altimeter Capital
Series C (2024): $50M backed by Wittington Ventures, Altimeter Capital, Radical Ventures, and Mubadala
Key Investors in Unlearn.AI
Mubadala
Mubadala is a global investment company based in Abu Dhabi, United Arab Emirates, focused on creating sustainable financial returns and diversifying the economy.
Altimeter Capital
Altimeter Capital is an investment firm that partners with technology companies from early growth through public markets, supporting product and strategy for durable value creation.
Radical Ventures
Radical Ventures is a venture capital firm specializing in artificial intelligence and deep technologies, investing in bold entrepreneurs aiming to invent the future.
What's next for Unlearn.AI?
The substantial enterprise-level funding, culminating in the recent $50M injection, positions Unlearn.AI for accelerated growth and market expansion. This strategic capital infusion is expected to fuel further development of its DiGenesis platform, enhance its AI capabilities, and broaden its application across more therapeutic areas. The company's focus on reducing clinical trial timelines and costs, while increasing data integrity, aligns with the growing demand for more efficient and effective drug development processes. Unlearn.AI's trajectory suggests a move towards scaling its operations and solidifying its position as a leader in AI-powered clinical trial solutions.
See full Unlearn.AI company page
